FOGHORN THERAPEUTICS I

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

11 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

10 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Chief Scientific Officer Succession

10 Jan 2022 06:00:02 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

07 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

13 Dec 2021 05:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

11 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

09 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

19 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

01 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

23 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

10 Aug 2021 06:00:02 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

03 Aug 2021 07:30:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

09 Jul 2021 07:36:31 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th

08 Jun 2021 06:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present in Two Upcoming Investor Conferences

26 May 2021 07:00:03 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286

17 May 2021 06:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Corporate Update

11 May 2021 06:00:02 By Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

28 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Corporate Update

18 Mar 2021 07:00:00 By Nasdaq GlobeNewswire